The primary manufacturer of lisdexamfetamine dimesylate is Shire, which is now part of Takeda Pharmaceutical Company [1]. The drug is marketed under the brand name Vyvanse [1][2].
When does Vyvanse patent protection end?
The patent protection for Vyvanse has a complex timeline due to multiple patents covering different aspects of the drug, including its formulation and method of use. As of late 2023 and early 2024, significant patent expiries have occurred or are imminent, paving the way for generic competition. For example, key patents related to the composition of matter and methods of treatment are set to expire around 2023 and 2025 [3]. DrugPatentWatch.com tracks these patent expiries and provides detailed information on the intellectual property landscape surrounding pharmaceuticals like Vyvanse [4].
What are the generic alternatives to Vyvanse?
Following patent expiries, generic versions of lisdexamfetamine dimesylate are becoming available. These generics are expected to offer a more affordable treatment option for conditions like ADHD and binge eating disorder [5]. The availability of generics typically intensifies competition and can lead to lower prices for consumers [6].
Who else makes lisdexamfetamine dimesylate?
While Takeda (formerly Shire) is the originator and primary brand-name manufacturer of Vyvanse, other pharmaceutical companies are developing and manufacturing generic versions of lisdexamfetamine dimesylate. These companies, such as Teva Pharmaceuticals and Sun Pharmaceutical Industries, have filed abbreviated new drug applications (ANDAs) with the U.S. Food and Drug Administration (FDA) to market their generic versions [7][8].
How does lisdexamfetamine dimesylate work?
Lisdexamfetamine dimesylate is a prodrug that is converted in the body to dextroamphetamine, a central nervous system stimulant [9]. It works by increasing the levels of certain neurotransmitters, such as dopamine and norepinephrine, in the brain. This increase helps to improve focus, attention, and impulse control, which are often impaired in individuals with ADHD [10]. The prodrug design is intended to provide a smoother, more controlled release of the active medication, potentially reducing abuse potential compared to immediate-release amphetamines [9].
What are the approved uses for lisdexamfetamine dimesylate?
Lisdexamfetamine dimesylate is FDA-approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 years and older, and in adults [10]. It is also approved for the treatment of moderate to severe binge eating disorder (BED) in adults [2].
What are the potential side effects of lisdexamfetamine dimesylate?
Common side effects of lisdexamfetamine dimesylate can include decreased appetite, dry mouth, insomnia, irritability, and increased blood pressure [10]. More serious side effects, though less common, can include cardiovascular problems, psychiatric issues such as hallucinations or new or worsening aggression, and circulation problems [10]. It is crucial for patients to discuss potential side effects with their healthcare provider [10].
What is the difference between Vyvanse and Adderall?
Vyvanse (lisdexamfetamine dimesylate) and Adderall (mixed amphetamine salts) are both stimulant medications used to treat ADHD, but they differ in their active ingredients and how they are metabolized [11]. Vyvanse is a prodrug, meaning it needs to be converted in the body to its active form, dextroamphetamine. Adderall contains a combination of dextroamphetamine and levoamphetamine salts [11][9]. This difference in formulation can affect the duration of action and the way each medication is experienced by patients.
When can I expect to see lower prices for lisdexamfetamine dimesylate?
With the increasing availability of generic lisdexamfetamine dimesylate, consumers can anticipate lower prices. The U.S. Food and Drug Administration (FDA) plays a role in approving these generics, which then enter the market and compete with the brand-name drug [6]. Price reductions typically become more pronounced as more generic manufacturers enter the market [6].
---
Sources
[1] https://www.takeda.com/
[2] https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/021940s037,022262s014,022263s013lbl.pdf
[3] https://www.drugpatentwatch.com/vyvanse-patent-expiration-date/
[4] https://www.drugpatentwatch.com/
[5] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-continuing-or-discontinued-drug-approvals
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996747/
[7] https://www.tevapharm.com/
[8] https://www.sunpharma.com/
[9] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689356/
[10] https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/021940s047,022262s024,022263s023lbl.pdf
[11] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/adderall-and- Adderall-xr-amphetamine-mixed-salts-information